PI3Kδinhibitors as immunomodulatory agents for the treatment of lymphoma patients
-
Tarantelli, Chiara
ORCID
Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, UniversitĂ della Svizzera italiana, Switzerland
-
Argnani, Lisa
ORCID
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy - Istituto di Ematologia “Serà gnoli”, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi di Bologna, Bologna, Italy
-
Zinzani, Pier Luigi
ORCID
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy - Istituto di Ematologia “Serà gnoli”, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi di Bologna, Bologna, Italy
-
Bertoni, Francesco
ORCID
Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, UniversitĂ della Svizzera italiana, Switzerland - Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
Show more…
Published in:
- Cancers. - 2021, vol. 13, p. 5535.
English
The development of small molecules able to block specific or multiple isoforms of phosphoinositide 3-kinases (PI3K) has already been an active field of research for many years in the cancer field. PI3Kδ inhibitors are among the targeted agents most extensively studied for the treatment of lymphoma patients and PI3Kδ inhibitors are already approved by regulatory agencies. More recently, it became clear that the anti-tumor activity of PI3K inhibitors might not be due only to a direct effect on the cancer cells but it can also be mediated via inhibition of the kinases in non-neoplastic cells present in the tumor microenvironment. T-cells represent an important component of the tumor microenvironment and they comprise different subpopulations that can have both anti- and pro-tumor effects. In this review article, we discuss the effects that PI3Kδinhibitors exert on the immune system with a particular focus on the T-cell compartment.
-
Collections
-
-
Language
-
-
Classification
-
Medicine
-
License
-
CC BY
-
Open access status
-
gold
-
Identifiers
-
-
Persistent URL
-
https://n2t.net/ark:/12658/srd1322802
Statistics
Document views: 42
File downloads:
- Bertoni_2021_MDPI_cancers.pdf: 99